Payment overview · 2025
General Payments
$730.00
33 reported records · 16 companies
Healthcare provider profile · identity verified
Michael Yu, M.D
Allopathic & Osteopathic Physicians|Family Medicine · NEWPORT BEACH, CA · NPI 1942240874
Verified facts
What the public records show
CMS Open Payments records show Michael Yu, M.D received $730.00 in general payments during 2025 across 33 reported records.
Amgen Inc. accounted for 16.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Edarbi, Eliquis, Gemtesa, Mounjaro, Ozempic, Rybelsus, Synthroid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Farxiga by this doctor in 2024.
Azurity Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported EDARBI as an associated drug or biological on 1140 records involving 805 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Edarbi by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Wegovy by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $117.75 | 16.1% | 6 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $116.72 | 16.0% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $78.40 | 10.7% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $73.44 | 10.1% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $72.55 | 9.9% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $43.35 | 5.9% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $41.88 | 5.7% | 2 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $30.36 | 4.2% | 1 | 2025 |
| Tanabe Pharma America, Inc. | Unresolved — no canonical attribution shown | $24.30 | 3.3% | 1 | 2025 |
| Bausch Health US, LLC | Unresolved — no canonical attribution shown | $22.97 | 3.1% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $20.54 | 2.8% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $20.20 | 2.8% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $19.98 | 2.7% | 1 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $17.15 | 2.4% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $16.63 | 2.3% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $13.78 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $730.00 | 33 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $78.40 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $72.55 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $65.91 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $65.91 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $58.98 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $51.84 | 3 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $51.84 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $43.35 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $41.88 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $36.82 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $36.62 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $36.62 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $32.80 | 1 | 2025 |
Source payment records
|
|||||
| EDARBI Normalized: edarbi |
Drug | Azurity Pharmaceuticals, Inc. | $30.36 | 1 | 2025 |
Source payment records
|
|||||
| Radicava Normalized: radicava |
Drug | Tanabe Pharma America, Inc. | $24.30 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $23.47 | 1 | 2025 |
Source payment records
|
|||||
| WELLBUTRIN Normalized: wellbutrin |
Drug | Bausch Health US, LLC | $22.97 | 1 | 2025 |
Source payment records
|
|||||
| AMYVID Normalized: amyvid |
Drug | Lilly USA, LLC | $22.24 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $20.54 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $20.54 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $20.20 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $20.20 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $19.98 | 1 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $17.15 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $16.63 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $13.78 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $13.78 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| EDARBI edarbi |
2025 | Edarbi | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 59 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 106 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
106 | 23 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
94 | 16 |
| Azurity Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | EDARBI open payments reported associated product |
CMS Open Payments — General Payments 1140 supporting records · 805 recipient NPIs · example record 1242666830 |
Edarbi · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
59 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
91 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 379 | 112 |
| Ezetimibe | Ezetimibe | 259 | 85 |
| Atorvastatin Calcium | Atorvastatin Calcium | 143 | 42 |
| Repatha Sureclick | Evolocumab | 125 | 16 |
| Amlodipine Besylate | Amlodipine Besylate | 122 | 35 |
| Pravastatin Sodium | Pravastatin Sodium | 117 | 39 |
| Levothyroxine Sodium | Levothyroxine Sodium | 112 | 31 |
| Losartan Potassium | Losartan Potassium | 110 | 32 |
| Synthroid | Levothyroxine Sodium | 106 | 23 |
| Gabapentin | Gabapentin | 96 | 30 |
| Farxiga | Dapagliflozin Propanediol | 94 | 16 |
| Jardiance | Empagliflozin | 91 | 21 |
| Metoprolol Succinate | Metoprolol Succinate | 89 | 22 |
| Azithromycin | Azithromycin | 76 | 59 |
| Alprazolam | Alprazolam | 75 | 22 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 72 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 71 | 17 |
| Metformin Hcl | Metformin Hcl | 65 | 17 |
| Eliquis | Apixaban | 59 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 51 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 48 | 13 |
| Allopurinol | Allopurinol | 44 | 11 |
| Tamsulosin Hcl | Tamsulosin Hcl | 44 | 13 |
| Montelukast Sodium | Montelukast Sodium | 41 | 11 |
| Alendronate Sodium | Alendronate Sodium | 39 | suppressed |
| Lisinopril | Lisinopril | 39 | 12 |
| Ozempic | Semaglutide | 38 | suppressed |
| Irbesartan | Irbesartan | 37 | 11 |
| Trulicity | Dulaglutide | 36 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 34 | 18 |
| Nebivolol Hcl | Nebivolol Hcl | 34 | suppressed |
| Mounjaro | Tirzepatide | 33 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 33 | 12 |
| Pantoprazole Sodium | Pantoprazole Sodium | 32 | 11 |
| Metformin Hcl Er | Metformin Hcl | 31 | suppressed |
| Valsartan | Valsartan | 30 | suppressed |
| Testosterone | Testosterone | 28 | suppressed |
| Mirtazapine | Mirtazapine | 27 | suppressed |
| Carvedilol | Carvedilol | 25 | suppressed |
| Omeprazole | Omeprazole | 25 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 25 | 15 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 24 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 23 | suppressed |
| Famotidine | Famotidine | 23 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 23 | 22 |
| Crestor | Rosuvastatin Calcium | 22 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 22 | suppressed |
| Memantine Hcl | Memantine Hcl | 21 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 21 | suppressed |
| Droxidopa | Droxidopa | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 13 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 19 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 14 |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 18 | suppressed |
| Furosemide | Furosemide | 18 | suppressed |
| Ramipril | Ramipril | 18 | suppressed |
| Bupropion Xl | Bupropion Hcl | 17 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 17 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 14 |
| Meloxicam | Meloxicam | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | 13 |
| Praluent Pen | Alirocumab | 16 | suppressed |
| Proair Respiclick | Albuterol Sulfate | 16 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 15 | suppressed |
| Calcitriol | Calcitriol | 15 | suppressed |
| Cephalexin | Cephalexin | 15 | 13 |
| Estradiol | Estradiol | 15 | suppressed |
| Livalo | Pitavastatin Calcium | 15 | suppressed |
| Gemtesa | Vibegron | 14 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 14 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 13 | suppressed |
| Lorazepam | Lorazepam | 13 | suppressed |
| Lubiprostone | Lubiprostone | 13 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 13 | suppressed |
| Spironolactone | Spironolactone | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Edarbi | Azilsartan Medoxomil | 11 | suppressed |
| Wegovy | Semaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $730.00 · 33 records | Amgen Inc. | AIRSUPRA, AMYVID, AREXVY, CAPVAXIVE, Cologuard Collection Kit, EDARBI, ELIQUIS, EVENITY, GARDASIL 9, GEMTESA, JATENZO, KISUNLA, LEQVIO, MOUNJARO, OTEZLA, Ozempic, PROLIA, REPATHA, Radicava, Rybelsus, SHINGRIX, SYNTHROID, The Cologuard Plus Collection Kit, UBRELVY, Veozah, WELLBUTRIN, ZEPBOUND | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Edarbi play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error